This week's Fierce Drug Delivery is brought to you by Catalent.

Trouble viewing? Click here.

webinar logos
 

Webinar: Use of PBPK Modeling for Predicting and Optimizing Controlled Release Dosage Forms

Monday, June 14, 2021 | 11am ET / 8am PT

  
 

API physicochemical and biopharmaceutic properties play a role in determining if the molecule is suitable for controlled release dosage forms. In this webinar, experts will share how dissolution tools and PBPK modeling can help evaluate whether a molecule is suitable for controlled release applications and predict the effects of release rate on in vitro performance. In addition, the experts will cover all aspects of oral controlled release technologies and discuss current strategies to select the optimal technology to meet the intended release profile.
 
 
Save Your Spot
 
 

Key Takeaway:

  • Overview of oral controlled release systems based on release mechanism and the latest insights into the development of in vivo predictive dissolution tools to establish in vitro–in vivo correlation (IVIVC)
  • Development of the Gastrointestinal Simulator (GIS) to study drug release profiles of dosage forms and its extrapolation to non-disintegrating controlled release systems
  • Key PK parameters needed for PBPK modelling of controlled release dosage forms and how to apply PBPK modelling to predict in vitro release profile needs
  • Review of the selection criteria for controlled-release oral solid dosage forms and understanding of how a single-unit versus multiparticulate modified release systems modulate the release profile of the API
 
 
Twitter Facebook Linkedin  
 
 

 

You are currently subscribed as [email protected]
If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe.
Refer to our Privacy Policy.

Fierce LifeSciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2020 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission.